Lyra therapeutics to present 52-week extension stage results for enlighten 1 phase 3 study for lyr-210 for the treatment of chronic rhinosinusitis at cosm 2025

Watertown, mass., may 07, 2025 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra), (“lyra” or the “company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (crs), today announced that the company plans to present results from the 52-week extension stage of the enlighten 1 phase 3 study for lyr-210, the company's lead product candidate for crs, at the annual combined otolaryngology spring meetings (cosm 2025) being held may 14-18 in new orleans.
LYRA Ratings Summary
LYRA Quant Ranking